Previous 10 | Next 10 |
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, tod...
MEI Pharma press release (NASDAQ:MEIP): Q3 GAAP EPS of -$0.07 beats by $0.11. Revenue of $9.7M (+19.8% Y/Y) beats by $6.26M. For further details see: MEI Pharma GAAP EPS of -$0.07 beats by $0.11, revenue of $9.7M beats by $6.26M
--MEI Begins Fourth Fiscal Quarter with $169.0 Million in Cash-- MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2022, and highlighted recent corporate ...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MEI Pharma, Inc. (“MEI” or the “Company”) (NASDAQ: MEIP) on behalf of MEI stockholders. Our investigation concerns whether MEI has ...
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright Global Investment Conference 2022. The company will present a company overview and business update available for o...
The shares of MEI Pharma (NASDAQ:MEIP) are trading lower in the premarket Monday after the clinical-stage biotech disclosed that the company had made errors in the revenue recognition for its collaboration with Japanese drugmaker, Kyowa Kirin Co., Ltd (OTCPK:KYKOF). As a result, revenue was o...
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, tod...
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two posters presenting preclinical data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 for zandelisib, a...
Top Penny Stocks To Buy According To Interesting Options Data Today If you’ve traded penny stocks for a while, you might have heard the term “whale” mentioned before. This refers to large-dollar trades made by either institutions or investors with deep pockets. Whet...
Gainers: Clever Leaves Holdings (CLVR) +33%. NextDecade (NEXT) +23%. Dynagas LNG (DLNG) +23%. Clarus Therapeutics (CRXT) +23%. Amylyx (AMLX) +20%. Hoegh LNG Partners LP (HMLP) +21%. Kidpik (PIK) +19%. Agrify (AGFY) +17%. NexImmune (NEXI) +17%. Joby Aviation (JOBY) +17%. Losers: Icosavax (ICVX...
News, Short Squeeze, Breakout and More Instantly...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...